Tumorigenicity of a combination of psoriasis therapies.
Coal tar, a tumour initiator, and dithranol, a tumour promoter, are used in the treatment of psoriasis. Topical treatment of mice with pharmaceutical formulations of these two agents, at therapeutic doses, induced skin papillomas in a classical two-stage carcinogenesis protocol, while treatment with either agent alone did not. This finding has implications for the use of both agents in combination in the treatment of psoriasis.
Phillips
D H
DH
Haddow Laboratories, Institute of Cancer Research, Belmont, Sutton, Surrey, UK.
Alldrick
A J
AJ
D000255:Adenosine Triphosphate / Q000378:metabolism; D000287:Administration, Topical; D000818:Animals; D000875:Anthralin / Q000008:administration & dosage / Q000633:toxicity*; D001564:Benzo(a)pyrene / Q000633:toxicity; D002273:Carcinogens / Q000008:administration & dosage / Q000633:toxicity*; D003033:Coal Tar / Q000008:administration & dosage / Q000633:toxicity*; D004247:DNA / Q000096:biosynthesis; D004273:DNA, Neoplasm / Q000096:biosynthesis; D005260:Female; D051379:Mice; D009824:Ointments; D010761:Phosphorus Radioisotopes; D011565:Psoriasis / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000139:chemically induced* / Q000473:pathology
D002273:Carcinogens; D004273:DNA, Neoplasm; D009824:Ointments; D010761:Phosphorus Radioisotopes; D001564:Benzo(a)pyrene; D003033:Coal Tar; D000255:Adenosine Triphosphate; D004247:DNA; D000875:Anthralin